Clinical Trial

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

Study acronym: TARA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate response or intolerance to Biologic DMARDs.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-07-31 -> 2026-01-15 2026-05-23
minor Completion moved earlier: 2028-12-30 -> 2026-12-31 2026-05-23
Trial Details
NCT Number NCT06020144
Lead Sponsor Hangzhou Highlightll Pharmaceutical Co., Ltd
Conditions Rheumatoid Arthritis
Enrollment 459 participants
Start Date 2023-11-15
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22